These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

105 related items for PubMed ID: 12486321

  • 1. Antihistone and other autoantibodies in beta-thalassemia major patients receiving iron chelators.
    Pradhan V, Badakere S, Ghosh K.
    Acta Haematol; 2003; 109(1):35-9. PubMed ID: 12486321
    [Abstract] [Full Text] [Related]

  • 2. Immune function in patients with beta thalassaemia receiving the orally active iron-chelating agent deferiprone.
    Loebstein R, Dalal I, Nisbet-Brown E, Berkovitch M, Meydan N, Andrews D, Loubser MD, Koren G, Roifman CM, Olivieri NF.
    Br J Haematol; 1997 Sep; 98(3):597-600. PubMed ID: 9332313
    [Abstract] [Full Text] [Related]

  • 3. Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox.
    Economou M, Printza N, Teli A, Tzimouli V, Tsatra I, Papachristou F, Athanassiou-Metaxa M.
    Acta Haematol; 2010 Sep; 123(3):148-52. PubMed ID: 20185899
    [Abstract] [Full Text] [Related]

  • 4. Chelation therapy and bone metabolism markers in thalassemia major.
    Pratelli L, Verri E, Fortini M, Marconi S, Zolezzi C, Fornasari PM, Gamberini MR, De Sanctis V.
    J Pediatr Endocrinol Metab; 2006 Nov; 19(11):1335-42. PubMed ID: 17220062
    [Abstract] [Full Text] [Related]

  • 5. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
    Ha SY, Chik KW, Ling SC, Lee AC, Luk CW, Lam CW, Ng IO, Chan GC.
    Hemoglobin; 2006 Nov; 30(2):263-74. PubMed ID: 16798652
    [Abstract] [Full Text] [Related]

  • 6. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ.
    Circulation; 2007 Apr 10; 115(14):1876-84. PubMed ID: 17372174
    [Abstract] [Full Text] [Related]

  • 7. Treatment with deferiprone (L1) in a thalassemic patient with bone lesions due to desferrioxamine.
    Mangiagli A, De Sanctis V, Campisi S, Di Silvestro G, Urso L.
    J Pediatr Endocrinol Metab; 2000 Jun 10; 13(6):677-80. PubMed ID: 10905396
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S, Pathare AV.
    Ann Hematol; 2006 May 10; 85(5):315-9. PubMed ID: 16450126
    [Abstract] [Full Text] [Related]

  • 10. Iron-chelation therapy with oral chelators in patients with thalassemia major.
    Uygun V, Kurtoglu E.
    Hematology; 2013 Jan 10; 18(1):50-5. PubMed ID: 23321010
    [Abstract] [Full Text] [Related]

  • 11. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.
    Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, Burt AD, Fleming KA.
    N Engl J Med; 1998 Aug 13; 339(7):417-23. PubMed ID: 9700174
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
    Elalfy MS, Adly AM, Wali Y, Tony S, Samir A, Elhenawy YI.
    Eur J Haematol; 2015 Nov 13; 95(5):411-20. PubMed ID: 25600572
    [Abstract] [Full Text] [Related]

  • 13. Sensorineural hearing loss in β-thalassemia patients treated with iron chelation.
    Osma U, Kurtoglu E, Eyigor H, Yilmaz MD, Aygener N.
    Ear Nose Throat J; 2015 Dec 13; 94(12):481-5. PubMed ID: 26670754
    [Abstract] [Full Text] [Related]

  • 14. Adherence to desferrioxamine and deferiprone and the impact of deferiprone co-prescription in thalassaemia major patients. Does the addition of deferiprone improve adherence?
    Kidson-Gerber G, Lindeman R.
    Br J Haematol; 2008 Aug 13; 142(4):679-80. PubMed ID: 18537970
    [No Abstract] [Full Text] [Related]

  • 15. Alternate use of deferiprone and desferrioxamine in primary school children with thalassaemia major.
    Aydinok Y, Nisli G, Kavakli K.
    Br J Haematol; 1999 Jul 13; 106(1):252-3. PubMed ID: 10444196
    [No Abstract] [Full Text] [Related]

  • 16. Three most common nonsynonymous UGT1A6*2 polymorphisms (Thr181Ala, Arg184Ser and Ser7Ala) and therapeutic response to deferiprone in β-thalassemia major patients.
    Dadheech S, Rao AV, Shaheen U, Hussien MD, Jain S, Jyothy A, Munshi A.
    Gene; 2013 Dec 01; 531(2):301-5. PubMed ID: 24036429
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of combined desferrioxamine and deferiprone versus single desferrioxamine therapy in patients with major thalassemia.
    Zareifar S, Jabbari A, Cohan N, Haghpanah S.
    Arch Iran Med; 2009 Sep 01; 12(5):488-91. PubMed ID: 19722772
    [Abstract] [Full Text] [Related]

  • 18. The effect of combined therapy with deferoxamine and deferiprone on serum ferritin level of beta-thalassemic patients.
    Mirbehbahani N, Jahazi A, Rahim Abad HH.
    Hematology; 2012 May 01; 17(3):183-6. PubMed ID: 22664119
    [Abstract] [Full Text] [Related]

  • 19. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
    Tanphaichitr A, Kusuwan T, Limviriyakul S, Atipas S, Pooliam J, Sangpraypan T, Tanphaichitr VS, Viprakasit V.
    Hemoglobin; 2014 May 01; 38(5):345-50. PubMed ID: 25051423
    [Abstract] [Full Text] [Related]

  • 20. Immune status of thalassemic patients receiving deferiprone or combined deferiprone and desferrioxamine chelation treatment.
    Athanassiou-Metaxa M, Tzimouli V, Economou M, Taparkou A, Tourkantoni N, Kanakoudi-Tsakalidou F.
    Acta Haematol; 2003 May 01; 110(4):224-6. PubMed ID: 14663175
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.